• EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?

  • Sep 26 2024
  • Durée: 50 min
  • Podcast

EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?

  • Résumé

  • This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:

    • Compares traditional ultrasound with advanced imaging techniques.
    • Examines AI-based approaches in patient classification.

    The episode concludes with a forward-looking perspective on the future management of MASLD.

    Faculty

    • Thomas Berg (Moderator)
    • Timm Denecke (Faculty)
    • Juan-Manuel Pericàs (Faculty)
    • Valérie Vilgrain (Faculty)

    This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.

    Related episodes

    • EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
    • EASL Studio S6E1: Do we solve MASLD by treating obesity?
    • EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance

    All EASL Studio Podcasts are available on EASL Campus.

    Voir plus Voir moins

Ce que les auditeurs disent de EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.